ArticleMolecular biology reports2026
TMPRSS2 rs12329760 variant as a prognostic marker for prostate cancer progression.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTMPRSS2, a transmembrane serine protease and common partner in oncogenic TMPRSS2-ERG fusions, is regulated by androgen receptors and is implicated in prostate tumorigenesis. The nonsynonymous SNP rs12329760 (C > T; Val160Met) has been hypothesized to alter TMPRSS2 proteolytic activity, potentially enhancing AR signaling and contributing to aggressive tumor behavior. However, data on this variant in North African populations remain sparse.
methodsA case-control study was conducted including 50 Moroccan men diagnosed with prostate cancer (PCa) and 50 matched controls. Genotyping of rs12329760 was performed using TaqMan allelic discrimination assays. Genotype and allele distributions were analyzed and correlated with clinicopathological factors, including serum PSA levels, Gleason score, family history, smoking status, and other demographic or clinical variables.
resultsThe CT (44% vs. 26%, P = 0.016) and TT (20% vs. 8%, P = 0.031) genotypes, as well as the T allele (43% vs. 21%, P = 0.002), were significantly more frequent in PCa patients than controls and were associated with increased disease risk. Carriers of the CT + TT genotypes exhibited significantly higher PSA levels (≥ 10 ng/mL, P = 0.004), Gleason scores (≥ 7, P = 0.018).Significant associations were also observed with positive family history (P < 0.001) and smoking (P < 0.001). No associations were found with age at diagnosis, T-stage.
conclusionsThe TMPRSS2 rs12329760 T allele is associated with elevated prostate cancer risk and more severe clinicopathological features in Moroccan men. These findings highlight the potential prognostic relevance of the V160M variant and emphasize the need for further cellular and molecular studies to elucidate its functional role in AR signaling, TMPRSS2-ERG fusion biology, and ERG-related tumor aggressiveness. Such insights may contribute to the development of risk-stratified PCa management and tailored active surveillance strategies.
Indexed as
Identifiers
41528570What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.